Pipeline
|
Program |
|---|
|
Program |
Discovery |
Lead candidate identification |
IND-enabling studies |
Phases 1-3 |
||||
|---|---|---|---|---|---|---|---|---|
|
NTX-250 Target HPV16 E6/E7, IL-12, LIGHT Modality Locally delivered, mRNA encoded immunotherapy with engineered LIGHT +IL-12 Indication High-grade cervical dysplasia, HPV-driven tumors |
||||||||
|
||||||||
|
NTX-470 Target PSMA-STEAP1 T Cell engager Modality Systemically delivered, mRNA encoded multi-specific protein Indication Metastatic, castration resistant prostate cancer |
||||||||
|
||||||||
|
NTX-472 Target aCD19-aCD20-SIRPα Modality Systemically delivered, mRNA encoded multi-specific protein Indication Auto-immune disease; R/R B cell lymphoma |
||||||||
|